Overview

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Nivolumab